Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China21 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Double-Blind Trial of Chrocare CDSS for Integrated Management of Type 2 Diabetes | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Urogenital Diseases, cardiovascular disorder, diabetes mellitus, diabetic kidney disease, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, glucose metabolism disease, kidney disorder, metabolic disease, retinal disorder, type 2 diabetes mellitus, urinary system disorder, vascular disorder | Not yet recruiting | Not applicable | 2026-09-22 | NCT07833228 | |
| A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma. | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 | 2026-08-14 | NCT06970496 | |
| SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 2 | 2026-07-23 | NCT07384234 | |
| A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, relapsed/refractory diffuse large B-cell lymphoma | Recruiting | Phase 3 | 2026-07-20 | NCT07409428 | |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04849728 | |
| Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-06-30 | NCT07527689 | |
| A Clinical Study of B007 in the Treatment of Pemphigus. | Skin and Connective Tissue Diseases, autoimmune disease, immune system disorder, pemphigus, skin disorder, vesiculobullous skin disease | Recruiting | Phase 2 / Phase 3 | 2026-05-05 | NCT06454357 | |
| Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-04-30 | NCT06497062 | |
| Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Phase 3 | 2026-04-06 | NCT07511127 | |
| PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL | Natural Killer/T-cell Lymphoma | Recruiting | Phase 2 | 2026-03-20 | NCT07380984 | |
| Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-23 | NCT04208347 | |
| A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 / Phase 2 | 2025-12-31 | NCT05800977 | |
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2025-12-15 | NCT06449586 | |
| A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation | KRAS G12D Mutation | Recruiting | Phase 1 / Phase 2 | 2025-10-30 | NCT06667544 | |
| SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal cancer, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Recruiting | Phase 2 | 2025-09-30 | NCT07198165 | |
| A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2025-07-20 | NCT06464991 | |
| VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, myeloid sarcoma, neoplasm, sarcoma | Recruiting | Phase 2 | 2025-07-09 | NCT07028086 | |
| A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Not yet recruiting | Phase 1 / Phase 2 | 2025-01-14 | NCT06774664 | |
| Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | Advanced Renal Cell Carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2025-01-03 | NCT05522231 | |
| A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B | Blood-Borne Infections, Chronic Disease, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Hepadnaviridae infectious disease, Hepatitis, Chronic, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, chronic hepatitis B virus infection, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Enrolling by invitation | Not applicable | 2024-12-04 | NCT06707922 | |
| Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 2 | 2024-10-22 | NCT06652685 |